Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
5
Not yet recruiting, industry sponsors, Gastroenterology and liver, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed158
5 trials
Showing 1 to 5, recently updated first.
- J-LINX: Japan LINerixibat eXtension StudyPivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07860710 · 40 participants (planned) · Start Oct 9, 2026 · Primary completion Oct 23, 2028
Drug: Linerixibat · For: Pruritus
- Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive EsophagitisPivotal-lookingNot yet recruiting
Onconic Therapeutics Inc.Industry
NCT07732075 · 384 participants (planned) · Start Aug 1, 2026 · Primary completion Oct 30, 2028
Drug: JP-1366 10 mg; Lansoprazole 15mg · For: Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)
- A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe HypertriglyceridemiaPivotal-lookingNot yet recruiting
Zhejiang Doer Biologics Co., Ltd.Industry
NCT07693777 · 480 participants (planned) · Start Aug 17, 2026 · Primary completion Feb 14, 2029
Drug: DR10624 Injection · For: Severe Hypertriglyceridemia (sHTG); Hypertriglyceridemia
Sites: Shanghai, China
- Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux DiseasePivotal-lookingNot yet recruiting
Onconic Therapeutics Inc.Industry
NCT07160790 · 321 participants (planned) · Start Sep 2, 2025 · Primary completion Jun 30, 2026
Drug: JP-1366 + placebo; Placebo + Placebo · For: Non-erosive Gastroesophageal Reflux Disease
- Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)Pivotal-lookingNot yet recruiting
Tasly Pharmaceutical Group Co., LtdIndustry
NCT06753890 · 520 participants (planned) · Start Dec 30, 2024 · Primary completion Nov 11, 2026
Drug: Changkang granules; Changkang Granules placebo · For: Diarrhea-predominant Irritable Boewl Syndrome
Sites: Baoding, China; Beijing, China; Changsha, China · 30 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.